Jalyn
Developed to alleviate benign prostatic hyperplasia symptoms to support urinary flow.
Strengths: 0.4/0.5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Combodart
- Therapeutic class
5-alpha reductase inhibitor and alpha-1 blocker combination
- Pharmacological class
5-alpha reductase inhibitor; alpha-1 adrenergic receptor antagonist
- Contraindications
history of postural hypotension; severe hepatic impairment; women; children
- Minor side effects
erectile dysfunction; decreased libido; ejaculation disorder; dizziness
- Moderate side effects
breast tenderness; gynaecomastia
- Serious side effects
angioedema — requires immediate medical attention
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
GlaxoSmithKline
- Onset Time
2–4 weeks
- Duration
Ongoing
- Storage instructions
Store at room temperature.
- Drug interactions
Alpha-blockers; CYP3A4 inhibitors
- Age restrictions
Adult males only.
Precautions and warnings
handle with caution as dutasteride is absorbed through skin; may cause dizziness; risk of intra-operative floppy iris syndrome
Patient summary
Developed to alleviate benign prostatic hyperplasia symptoms to support urinary flow.
Mechanism of action
Dutasteride shrinks the prostate by inhibiting 5-alpha reductase, while tamsulosin relaxes smooth muscle in the prostate and bladder neck to improve urine flow.
Pregnancy and breastfeeding
Pregnancy: Women who are pregnant or may be pregnant should not handle the capsule. Breastfeeding: Not applicable.
Jalyn
Developed to alleviate benign prostatic hyperplasia symptoms to support urinary flow.
Editorial Notes
- Active ingredient(s): Dutasteride, Tamsulosin
- Listed indication(s): Benign Prostatic Hyperplasia
Available option
- 30 tablets - 0.4/0.5 mg1479-0-4-0-5-mg-18081